{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"Mix of previously treated \\& newly diagnosed pts (populations which may have different prognoses), plus the relatively small trial size limit conclusions one can draw re: relative efficacy of MDV (vs CyBorD or Mel-Dex, for example)"},"pointOfContact":{"email":"zonderj@karmanos.org","organization":"Barbara Ann Karmanos Cancer Institute","phone":"313-576-8732","title":"Jeffrey Zonder, M.D."}}